Clinical trial
First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years…
NCT03492775 · Prof. Dr. Wolfgang Hiddemann, Other · Completed
Key facts
| NCT number | NCT03492775 |
|---|---|
| Title | First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years |
| Official title | Prospective Randomized Evaluation of Single Agent GA101 Versus GA101 Plus Bendamustine Followed by GA101 |
| Acronym | GABe2016 |
| Lead sponsor | Prof. Dr. Wolfgang Hiddemann, Other |
| Collaborators | Hoffmann-La Roche Industry Mundipharma Research GmbH & Co KG |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Indolent Non-hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | Obinutuzumab, Bendamustine |
| Enrollment | 46 |
| Start date | Dec 12, 2017 |
| Primary completion | Nov 30, 2021 |
| Completion | Dec 31, 2022 |
| First posted | Apr 10, 2018 |
| Last update posted | Mar 31, 2023 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: